Procrea’s Genetic Microarray Analysis CombiGene® test offers physicians, couples with a family history of genetic anomalies and pregnant women, whose prenatal screening or prenatal ultrasound indicate a high risk of carrying a baby with Down’s Syndrome or other genetic diseases. The CombiGene® test provides a precise, highly accurate, cost effective result, far exceeding the results obtained by conventional chromosomal analysis*. CombiGene® test has the ability to detect, simultaneously, over 150 anomalies that are not detected by conventional techniques including the following syndromes and conditions:
- Telomere deletion
- Uniparental disomy (UPD)1
1 UPD syndromes such as Prader-Willi are not detected by standard cytogenetics, comparative genomic hybridization (Array-CGH), fluorescence in situ hybridization (FISH) or quantitative enriched real-time PCR (QEPCR).
When is the CombiGene® test used?
- Abnormal prenatal screening results
- Advanced maternal age
- A family history of:
◦ Chromosome abnormalities
◦ Risk of a known genetic anomaly or mental retardation
◦ Known inherited disorders
- Abnormal fetal ultrasound signs:
◦ Cardiac anomalies
◦ Echogenic cardiac foci
◦ Growth development delays
- Ambiguous genitalia
- Birth defects
- Dysmorphic features
- Chromosome abnormalities (deletion, duplication)
- Mental retardation of unknown etiology
- Growth development delays
- Primary amenorrhea
- Male or female infertility
The clinical laboratory of Procrea Fertility is one of the few institutions having access to an advanced technology that permits the detection of a vast array of diseases. We offer you the service based on the latest technologies in genetic testing. At Procrea Fertility our laboratory professionals and our genetic counselors will provide you, patient and physician, with a detailed diagnosis and crucial information on the results obtained. Speak with your physician to learn if the CombiGene® test is right for you, and available at your Procrea Fertility location.
*The American College of Obstetricians and Gynecologists, OB-GYNs Recommend Chromosomal Microarray Analysis for Genetic Evaluation of fetal Anomalies, November 2013.
CombiGene® is a registered trademark of GROUPE OPMEDIC INC.